2. Search Result
Search Result
Results for "

weakness

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99355
    Bimagrumab
    1 Publications Verification

    Anti-ACVR2B Reference Antibody; BYM338

    		 TGF-β Receptor Metabolic Disease
    Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
    Bimagrumab
  • HY-N2522
    Carboxyatractyloside dipotassium
    2 Publications Verification

    Gummiferin dipotassium

    		 Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium
  • HY-N1502
    Carboxyatractyloside tripotassium
    2 Publications Verification

    Gummiferin tripotassium

    		 Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel Neurological Disease
    Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside tripotassium
  • HY-158183
    NMD670

    		Chloride Channel Neurological Disease
    NMD670 is an orally active inhibitor of skeletal muscle specific chloride channel ClC-1 with an EC50 of 1.6 μM. NMD670 enhances neuromuscular transmission and improves muscle contraction and strength. NMD670 can be used in the study of muscle weakness and muscle fatigue .
    NMD670
  • HY-100186
    GSK-2881078
    4 Publications Verification

    		 Androgen Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness .
    GSK-2881078
  • HY-P3502
    Zilucoplan

    RA101495; RA3193

    		 Complement System Inflammation/Immunology
    Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .
    Zilucoplan
  • HY-15344
    Ketone monoester
    2 Publications Verification

    		 Biochemical Assay Reagents Neurological Disease Metabolic Disease
    Ketone monoester is an orally available ketone monoester that serves as a source of nutritional ketones. Ketone monoester increases plasma beta-hydroxybutyrate, acetoacetate, blood glucose, blood sodium, and blood creatinine levels in mouse models. Ketone monoester has the potential to improve athletic performance and endurance in animals. Ketone monoester partially prevents myasthenia in septic mice. Ketone monoester may also be used to study Parkinson's disease or diabetes .
    Ketone monoester
  • HY-N2522R
    Carboxyatractyloside dipotassium (Standard)

    Gummiferin dipotassium (Standard)

    		 Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium (Standard)
  • HY-114081A
    Hemicholinium chloride

    HC-3 chloride

    		 Choline Kinase Neurological Disease
    Hemicholinium chloride (HC-3) is a choline kinase (ChoK) inhibitor. Hemicholinium chloride Hemicholinium chloride induces ataxia and muscular weakness .
    Hemicholinium chloride
  • HY-15344A
    (S,S)-Ketone monoester

    		Drug Isomer Neurological Disease
    (S,S)-Ketone monoester is a (S,S)-enantiomer of Ketone monoester (HY-15344). Ketone monoester elevates the AcAc and acetone levels, thereby produces sustained ketosis and significantly delays central nervous system oxygen toxicity (CNS-OT) seizures .
    (S,S)-Ketone monoester

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: